Total Payments
$9,007
2024 Payments
$1,090
Companies
39
Transactions
510
Medicare Patients
6,058
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$8,541 (94.8%)
Education$466.60 (5.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,541 | 489 | 94.8% |
| Education | $466.60 | 21 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fresenius USA Marketing, Inc. | $1,575 | 99 | $0 (2024) |
| Amgen Inc. | $1,302 | 61 | $0 (2024) |
| Relypsa, Inc. | $870.79 | 69 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $712.58 | 38 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $525.76 | 28 | $0 (2024) |
| OPKO Pharmaceuticals, LLC | $512.59 | 30 | $0 (2024) |
| Travere Therapeutics, Inc. | $417.59 | 26 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $365.74 | 15 | $0 (2024) |
| Vifor Pharma, Inc. | $362.01 | 24 | $0 (2023) |
| GlaxoSmithKline, LLC. | $270.44 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,090 | 54 | Fresenius USA Marketing, Inc. ($385.71) |
| 2023 | $1,292 | 67 | Travere Therapeutics, Inc. ($263.61) |
| 2022 | $1,516 | 85 | Fresenius USA Marketing, Inc. ($384.37) |
| 2021 | $1,356 | 82 | Fresenius USA Marketing, Inc. ($466.34) |
| 2020 | $947.40 | 52 | Relypsa, Inc. ($291.81) |
| 2019 | $1,412 | 87 | Relypsa, Inc. ($321.39) |
| 2018 | $786.39 | 51 | Relypsa, Inc. ($179.64) |
| 2017 | $606.87 | 32 | OPKO Pharmaceuticals, LLC ($102.48) |
All Payment Transactions
510 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/06/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/06/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $15.96 | General |
| Category: Nephrology | ||||||
| 10/30/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/29/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/23/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/17/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $18.93 | General |
| Category: NEPHROLOGY | ||||||
| 10/09/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $14.50 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/09/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $8.95 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Diabetes | ||||||
| 10/02/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $14.79 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/11/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $23.92 | General |
| Category: Nephrology | ||||||
| 09/05/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $27.36 | General |
| Category: Diabetes | ||||||
| 09/04/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $14.72 | General |
| Category: NEPHROLOGY | ||||||
| 08/29/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Phosphate binder for ESRD | ||||||
| 08/14/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: Nephrology | ||||||
| 08/09/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/31/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/31/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $8.41 | General |
| Category: Inflammation/Rare Disease | ||||||
| 07/26/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: Diabetes | ||||||
| 07/24/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: IMMUNOLOGY | ||||||
| 07/17/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/03/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/28/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $37.93 | General |
| Category: IMMUNOLOGY | ||||||
| 06/26/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Nephrology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 1,495 | 18,906 | $771,142 | $385,943 |
| 2022 | 25 | 1,434 | 18,791 | $639,144 | $310,391 |
| 2021 | 27 | 1,520 | 19,588 | $712,272 | $354,069 |
| 2020 | 25 | 1,609 | 18,452 | $769,086 | $350,285 |
Total Patients
6,058
Total Services
75,737
Medicare Billing
$1.4M
Procedure Codes
122
All Medicare Procedures & Services
122 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 103 | 597 | $286,560 | $176,049 | 61.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 32 | 2,040 | $71,400 | $36,269 | 50.8% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 13 | 3,990 | $59,850 | $31,924 | 53.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 52 | 98 | $47,040 | $24,025 | 51.1% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 19 | 91 | $43,680 | $22,227 | 50.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 183 | 337 | $35,385 | $21,862 | 61.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 241 | $36,150 | $9,455 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 60 | 61 | $16,480 | $8,679 | 52.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 79 | 133 | $19,817 | $6,847 | 34.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 16 | 960 | $17,280 | $5,969 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 84 | $16,800 | $4,723 | 28.1% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 18 | 57 | $10,260 | $4,107 | 40.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 53 | 69 | $12,420 | $4,031 | 32.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 15 | 9,180 | $18,360 | $3,730 | 20.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 18 | 30 | $9,000 | $3,555 | 39.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 36 | 68 | $17,000 | $3,501 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 23 | 36 | $8,244 | $2,853 | 34.6% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 58 | 69 | $4,140 | $2,850 | 68.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 75 | 89 | $6,675 | $2,245 | 33.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 75 | 156 | $6,240 | $1,914 | 30.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 22 | 22 | $4,400 | $1,369 | 31.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 79 | 131 | $1,441 | $1,100 | 76.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 41 | $4,100 | $1,029 | 25.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 13 | 14 | $1,120 | $1,007 | 89.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 26 | 29 | $4,349 | $977.34 | 22.5% |
About Dr. Michael Dicus, MD
Dr. Michael Dicus, MD is a Nephrology healthcare provider based in Salinas, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447339452.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Dicus, MD has received a total of $9,007 in payments from pharmaceutical and medical device companies, with $1,090 received in 2024. These payments were reported across 510 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($8,541).
As a Medicare-enrolled provider, Dicus has provided services to 6,058 Medicare beneficiaries, totaling 75,737 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 122 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Salinas, CA
- Active Since 11/02/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1447339452
Products in Payments
- Velphoro (Drug) $1,545
- Veltassa (Drug) $1,233
- LOKELMA (Drug) $533.44
- Kerendia (Drug) $525.76
- Parsabiv (Drug) $447.40
- Aranesp (Biological) $389.23
- RAYALDEE (Drug) $343.98
- BENLYSTA (Biological) $270.44
- KRYSTEXXA (Biological) $261.94
- LUPKYNIS (Drug) $226.65
- JYNARQUE (Drug) $220.77
- Rituxan (Biological) $183.86
- Rayaldee (Drug) $168.61
- FARXIGA (Drug) $166.86
- ACTHAR (Biological) $156.96
- EPOGEN (Biological) $153.63
- SAMSCA (Drug) $144.97
- Ozempic (Drug) $131.41
- INJECTAFER (Drug) $105.02
- AURYXIA (Drug) $104.15
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.